NEW YORK - Ua'ōleloʻo Immunocore i ka Pōʻakahi e kūʻai akuʻo ia i nā'āpana 3,733,333 i loko o kahiʻaelike hoʻolimalima kālā pilikino (PIPE) i manaʻoʻia e hoʻonui i $ 140 miliona.
Ma lalo o kaʻaelike, e kūʻai aku anaʻo Immunocore i kāna kumukūʻai maʻamau a me ka mea kohoʻole no $ 37.50 no kēlā me kēia mahele. ʻO nā mea hoʻolale kālā o ka hui i kēia manawa e komo ana i ke kālā,ʻo ia hoʻiʻo RTW Investments, Rock Springs Capital a me General Atlantic. Ua manaʻoʻia e pau kaʻaelike PIPE ma Iulai 20.
E hoʻohana ka hui i nā mea i loaʻa no ke kālā i kāna mau moho oncology a me nā maʻi maʻi maʻi maʻi, me ka hoʻomohala ʻana i kāna moho oncology alakaʻi, ʻo Kimmtrak (tebentafusp-tebn), e mālama i ka HLA-A*02:01 maikaʻi ʻili a me ka uveal melanoma. ʻO ke kālā, me ka loaʻa kālā mai Kimmtrak, ua manaʻo ʻia e uku kālā i nā hana a Immunocore2025 ma o ka hana a Immunocore2025.
I kēia makahiki, ua'āponoʻiaʻo Kimmtrak no ka hoʻohanaʻana i nā maʻi me HLA-A * 02: 01 maikaʻi unresectable a iʻole metastatic uveal melanoma ma US, Europe a me UK, ma waena o nā'āina'ē aʻe.
Ke hoʻomohala nei ʻo Immunocore i ʻehā mau moho oncology ʻē aʻe, e komo pū ana ʻelua mau lāʻau lapaʻau T-cell receptor hou i nā hoʻokolohua Phase I / II i nā maʻi maʻi paʻa paʻa.
Privacy Policy.terms and Conditions.Copyright © 2022 GenomeWeb, he hui ʻoihana o Crain Communications. mālama ʻia nā kuleana āpau.